ICYMI: Thanks to CBC’s Quirks and Quarks for re-running this November 2020 interview with our co-founder, Dr. Molly Shoichet.
She spoke with Bob McDonald about winning the Gerhard Herzberg Canada Gold Medal and her research in hydrogel materials. AMT-143, our lead product, is grounded in this research and is currently approved for a Phase I clinical trial.
Listen to the interview or read the news story.
AmacaThera, a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform, announced the closing of a CAD$4.0 million financing round.Read more
AmacaThera collaborates with University Health Network to evaluate the economic impact of post-surgical opioid use. They are developing non-opioid analgesic, AMT-143, aiming to reduce the reliance on opioid medications.Read more
AmacaThera Inc today announced that the first subjects have been dosed in the company's Phase 1 first-in-human clinical investigation of the safety of AmacaGel™.Read more